Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320)

Next Previous
Trial Profile

An Open-label, Multicenter Phase Ib Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the ATR Inhibitor Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitors or Immune Checkpoint Inhibitors in Patients With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 320)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Lartesertib (Primary) ; Tuvusertib (Primary)
  • Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Ovarian cancer; Prostate cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms DDRiver Solid Tumors 320
  • Sponsors EMD Serono Research & Development Institute

Most Recent Events

  • 04 Jul 2025 Planned End Date changed from 31 May 2026 to 3 Apr 2026.
  • 04 Jul 2025 Planned primary completion date changed from 31 Mar 2026 to 3 Apr 2026.
  • 21 May 2025 Planned number of patients changed from 72 to 123.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top